Thirty-eight states and DC now permit medicinal or recreational marijuana use, giving rise to a $13b cannabis industry. Psychedelic entrepreneurs and activists are looking to this market for lessons. But while the cannabis and psychedelic markets share a similar outline— federal drug prohibition followed by and local and statewide reform initiatives—significant differences exist. Join us to explore what the budding psychedelic marketplace can learn from cannabis, as well as their critical differences.